Literature DB >> 20539224

Treatment of hyponatremia.

Richard H Sterns1, John Kevin Hix, Stephen Silver.   

Abstract

PURPOSE OF REVIEW: We review literature from the past 18 months on the treatment of hyponatremia. Therapy must address both the consequences of the untreated electrolyte disturbance (including fatal cerebral edema due to acute water intoxication) and the complications of excessive therapy (the osmotic demyelination syndrome). RECENT
FINDINGS: Correction of hyponatremia by 4-6 mEq/l within 6 h, with bolus infusions of 3% saline if necessary, is sufficient to manage the most severe manifestations of hyponatremia. Planning therapy to achieve a 6 mEq/l daily increase in the serum sodium concentration can avoid iatrogenic brain damage by staying well clear of correction rates that are harmful. Conservative correction goals are wise because inadvertent overcorrection is common. Administration of desmopressin to halt a water diuresis can help prevent overcorrection; if overcorrection occurs, therapeutic relowering of the serum sodium concentration is supported by data in experimental animals and was found to be safe in a small observational clinical trial. Even mild and apparently asymptomatic hyponatremia may lead to falls because of impaired gait, and an increased likelihood of fracture because of hyponatremia-induced osteoporosis, a newly described entity. Recently approved vasopressin antagonists now make it possible to normalize the serum sodium concentration on a chronic basis, but practical considerations have limited their use.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20539224     DOI: 10.1097/MNH.0b013e32833bfa64

Source DB:  PubMed          Journal:  Curr Opin Nephrol Hypertens        ISSN: 1062-4821            Impact factor:   2.894


  18 in total

Review 1.  Vasopressin receptor antagonists.

Authors:  Biff F Palmer
Journal:  Curr Hypertens Rep       Date:  2015-01       Impact factor: 5.369

2.  Vacuolar pathology in the median eminence of the hypothalamus after hyponatremia.

Authors:  Seymour Levine; Arthur Saltzman; Stephen D Ginsberg
Journal:  J Neuropathol Exp Neurol       Date:  2011-02       Impact factor: 3.685

3.  Risk Factors and Outcomes of Rapid Correction of Severe Hyponatremia.

Authors:  Jason C George; Waleed Zafar; Ion Dan Bucaloiu; Alex R Chang
Journal:  Clin J Am Soc Nephrol       Date:  2018-06-05       Impact factor: 8.237

Review 4.  Impact of perioperative hyponatremia in children: A narrative review.

Authors:  Cheme Andersen; Arash Afshari
Journal:  World J Crit Care Med       Date:  2014-11-04

Review 5.  SIAD: practical recommendations for diagnosis and management.

Authors:  M Cuesta; A Garrahy; C J Thompson
Journal:  J Endocrinol Invest       Date:  2016-04-19       Impact factor: 4.256

6.  Use of desmopressin acetate in severe hyponatremia in the intensive care unit.

Authors:  Cédric Rafat; Frédérique Schortgen; Stéphane Gaudry; Fabrice Bertrand; Romain Miguel-Montanes; Vincent Labbé; Jean-Damien Ricard; David Hajage; Didier Dreyfuss
Journal:  Clin J Am Soc Nephrol       Date:  2013-11-21       Impact factor: 8.237

7.  Treatment response in osmotic demyelination syndrome presenting as severe parkinsonism, ptosis and gaze palsy.

Authors:  Sanihah Abdul Halim; Nur Aida Mohd Amin
Journal:  BMJ Case Rep       Date:  2018-10-21

8.  Hypernatremia in a patient treated with sodium polystyrene sulfonate.

Authors:  Manish Nepal; Ion Dan Bucaloiu; Evan R Norfolk
Journal:  Int J Nephrol Renovasc Dis       Date:  2010-11-16

Review 9.  Management of severe hyponatremia: infusion of hypertonic saline and desmopressin or infusion of vasopressin inhibitors?

Authors:  Antonios H Tzamaloukas; Joseph I Shapiro; Dominic S Raj; Glen H Murata; Robert H Glew; Deepak Malhotra
Journal:  Am J Med Sci       Date:  2014-11       Impact factor: 2.378

10.  Hourly oral sodium chloride for the rapid and predictable treatment of hyponatremia.

Authors:  Eric Kerns; Shweta Patel; David M Cohen
Journal:  Clin Nephrol       Date:  2014-12       Impact factor: 0.975

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.